NOVN.CH

113.36

-2.34%↓

LONN.CH

481.8

-3.41%↓

SDZ.CH

63.06

-2.02%↓

STMN.CH

84.48

-1.38%↓

BANB.CH

68.1

+0.89%↑

NOVN.CH

113.36

-2.34%↓

LONN.CH

481.8

-3.41%↓

SDZ.CH

63.06

-2.02%↓

STMN.CH

84.48

-1.38%↓

BANB.CH

68.1

+0.89%↑

NOVN.CH

113.36

-2.34%↓

LONN.CH

481.8

-3.41%↓

SDZ.CH

63.06

-2.02%↓

STMN.CH

84.48

-1.38%↓

BANB.CH

68.1

+0.89%↑

NOVN.CH

113.36

-2.34%↓

LONN.CH

481.8

-3.41%↓

SDZ.CH

63.06

-2.02%↓

STMN.CH

84.48

-1.38%↓

BANB.CH

68.1

+0.89%↑

NOVN.CH

113.36

-2.34%↓

LONN.CH

481.8

-3.41%↓

SDZ.CH

63.06

-2.02%↓

STMN.CH

84.48

-1.38%↓

BANB.CH

68.1

+0.89%↑

Search

Roche Holding AG

Cerrado

SectorSanidad

330.4 -0.78

Resumen

Variación precio

24h

Actual

Mínimo

329.6

Máximo

330.6

Métricas clave

By Trading Economics

Ingresos

1.8B

5.5B

Ventas

15B

31B

P/B

Media del Sector

20.599

60.328

Rentabilidad por dividendo

2.95

Margen de beneficios

17.892

Empleados

103,249

EBITDA

5.1B

12B

Dividendos

By Dow Jones

Rentabilidad por dividendo

Media del Sector

2.95%

2.24%

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

-26B

263B

Apertura anterior

331.18

Cierre anterior

330.4

Noticias sobre sentimiento de mercado

By Acuity

50%

50%

155 / 348 Clasificación en Healthcare

Roche Holding AG Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

23 abr 2026, 07:46 UTC

Ganancias

Roche Backs Full-Year View as Quarterly Sales Rise -- Update

23 abr 2026, 05:40 UTC

Ganancias

Roche Backs Full-Year View as Quarterly Sales Rise

9 mar 2026, 16:43 UTC

Principales Movimientos del Mercado

Roche Shares Fall After Breast-Cancer Treatment Misses Goal in Late-Stage Study -- Update

9 mar 2026, 15:44 UTC

Principales Movimientos del Mercado

Correction to Roche Shares Article

9 mar 2026, 09:51 UTC

Principales Movimientos del Mercado

Roche Shares Fall After Breast-Cancer Treatment Misses Goal in Late-Stage Study

6 mar 2026, 09:24 UTC

Principales Movimientos del Mercado

Zealand Pharma Shares Plunge After Obesity Drug Candidate Disappoints in Trial

29 ene 2026, 10:07 UTC

Ganancias

Roche Forecasts 2026 Growth, Cites Drug-Pipeline Strength -- Update

29 ene 2026, 07:07 UTC

Ganancias

Roche Forecasts 2026 Growth, Helped by Strength of Drug Pipeline

23 abr 2026, 08:10 UTC

Charlas de Mercado
Ganancias

Roche Reports In Line Sales Figures -- Market Talk

23 abr 2026, 05:04 UTC

Ganancias

Roche Backs 2026 View

23 abr 2026, 05:04 UTC

Ganancias

Roche Diagnostics Division 1Q Sales Up at 3% Constant Currency

23 abr 2026, 05:03 UTC

Ganancias

Roche Pharmaceutical Division 1Q Sales Up 7% at Constant Currency

23 abr 2026, 05:02 UTC

Ganancias

Roche 1Q Group Sales Up 6% at Constant Currency

23 abr 2026, 05:02 UTC

Ganancias

Analysts Saw Roche 1Q Sales at CHF14.73B

23 abr 2026, 05:01 UTC

Ganancias

Roche 1Q Sales CHF14.72B

10 abr 2026, 11:28 UTC

Charlas de Mercado

Roche's Longer-Term Outlook to Take Spotlight at Diagnostics Event -- Market Talk

10 abr 2026, 11:17 UTC

Charlas de Mercado

Roche to Face Significant Currency Headwinds -- Market Talk

11 mar 2026, 10:57 UTC

Charlas de Mercado

Roche Sees Mixed Fortunes in Immunology, Oncology -- Market Talk

9 mar 2026, 09:43 UTC

Acciones populares

Stocks to Watch Monday: Lamb Weston, Carnival, Pfizer -- WSJ

6 mar 2026, 07:22 UTC

Charlas de Mercado

Roche, Zealand Pharma Obesity Drug Falls Short of Expectations -- Market Talk

3 mar 2026, 07:22 UTC

Charlas de Mercado

Roche's Multiple Sclerosis Drug Safety Remains in Focus After Latest Trial -- Market Talk

2 mar 2026, 14:21 UTC

Charlas de Mercado

Roche's Multiple Sclerosis Drug Might Not Clear FDA Bar -- Market Talk

29 ene 2026, 11:40 UTC

Charlas de Mercado
Ganancias

Roche's Guidance Seems Less Conservative Than Expected -- Market Talk

29 ene 2026, 06:05 UTC

Ganancias

Roche Expects 2026 Core EPS to Increase in High-Single Digit Range at CER

29 ene 2026, 06:04 UTC

Ganancias

Roche Expects 2026 Mid-Single-Digit Range Sales Increase at Constant Currency

29 ene 2026, 06:03 UTC

Ganancias

Roche Issues 2026 View

29 ene 2026, 06:02 UTC

Ganancias

Analysts Saw 2025 Core EPS at CHF19.70

29 ene 2026, 06:02 UTC

Ganancias

Roche: 2025 Core EPS CHF19.46

29 ene 2026, 06:01 UTC

Ganancias

Analysts Had Seen 2025 Sales At CHF61.47B

29 ene 2026, 06:01 UTC

Ganancias

Roche 2025 Sales CHF61.52B

Comparación entre iguales

Cambio de precio

Roche Holding AG previsión

Consenso

By TipRanks

0 ratings

0

Comprar

0

Mantener

0

Vender

Sentimiento

By Acuity

155 / 348 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Neutral

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Roche Holding AG

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It is also developing products for various therapeutic areas. In addition, it offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases; diagnostic instruments; and digital health solutions. It has strategic discovery collaboration with Flare Therapeutics Inc. proteomic and mass spectrometry platform and expertise to discover novel small molecules aimed at transcription factor targets in oncology. Roche Holding AG was founded in 1896 and is based in Basel, Switzerland.